Federal Association of Pharmaceutical Industries BPI
AMNOG 2022 data from the Federal Association of the Pharmaceutical Industry (BPI) shows that a very large number of medicinal products, currently one in eight, still leave the market after undergoing the AMNOG process. As a result, these innovations are no longer available to patients in this country. The Statutory Health Insurance Financial Stability Act could reinforce this trend.
Each gap in availability that arises with exit from the market can also lead to a supply gap if a drug cannot be substituted therapeutically or can only be replaced with difficulty. The number of market exits could also increase as a result of the AMNOG review provided for in the GKV Financial Stability Act. Because, according to the bill, only preparations with very rare categories of “large and significant additional benefit” can bring in a higher amount in the future, important incentives to invest in innovations and thus in better care in Germany will be lost. The core principle of AMNOG will simply be thrown overboard: the goal will no longer be to reward therapeutic progress, but to turn AMNOG into a pure cost-saving tool.
The AMNOG 2022 data also shows that innovative drugs that include patient data on quality of life as part of an assessment of early benefits are rated better overall. “However, in no way did the G-BA take into account all the quality-of-life data provided,” the authors wrote, health economists Professor Dieter Kassel and Professor Volker Ulrich. On average, the proportion of quality of life data provided was 62 percent, peaking at 71 percent (2017).
“AMNOG data”, written by Cassel and Ulrich and published by BPI in year 6, provides detailed information on the basics, processes and outcomes for assessing additional benefits and pricing of innovative medicines in Germany and deals with important aspects of AMNOG regulation: how many procedures have been performed so far? How often has an additional benefit of new preparations been recognized? Are there special assessments in individual therapeutic areas? How does benefit assessment affect reimbursement amount agreements? What are the results of the arbitration proceedings? Are there any unwanted side effects on patient care? How do the prices of pharmaceutical innovations evolve and how do shares of spending on innovative pharmaceuticals evolve over time?
The AMNOG 2022 data and all associated figures can be accessed directly via Homepage Download or read the BPI at the BPI kiosk or order the brochure for free at the BPI office.
Contact: Andreas Aumann (press spokesperson), tel. 03027909-123, email@example.com
Original content from: BPI Federal Association of the Pharmaceutical Industry, transmitted by aktuell news